A Phase II, Multi-Center, Extension Study to Evaluate the Safety and Efficacy of Celgosivir in Combination With Peginterferon Alfa-2b, With or Without Ribavirin, for an Additional 36 Weeks.
Phase of Trial: Phase II
Latest Information Update: 06 Apr 2010
At a glance
- Drugs Celgosivir; Peginterferon alfa-2b; Ribavirin
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- Sponsors Carrus Capital Corporation
- 18 Jan 2008 Status changed from in progress to completed according to ClinicalTrials.gov.
- 15 Apr 2007 Status changed from recruiting to in progress.
- 23 Oct 2006 New trial record.